A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines

Challenge: The fight against cancer, infectious diseases and chronic disorders has been significantly advanced because of the development of effective immunotherapies, vaccines and immunomodulatory drugs. New pre-clinical tools to enable this new active field of drug discovery are needed further upstream in the discovery process. More functional and physiologically relevant readouts are necessary to address…

VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles

Challenge: Despite the enormous benefits that traditional vaccines have brought to human health in the last century, preventable diseases continue to claim millions of lives each year. New vaccine technologies that offer speed and versatility in production would have significant impact. The emergence of technologies based on Virus-Like Particles (VLPs) has paved the way for…

A novel phage-based screening technology for antiviral

Challenge: Infection with herpes viruses is associated with several immunodeficient human diseases including the development of cancers. Patients receiving organ transplants are particularly sensitive to such infections. These patients are treated with antiviral agents; however, approved drugs are often associated with severe side effects and the development of resistance can compromise therapy. There is thus…

In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)

Challenge: Lupus is a chronic autoimmune disease in which the body immune system attacks its own tissues, causing inflammation and tissue damage. Systemic lupus erythematosus (SLE) is the most common type. It affects 1/1000 individuals, mostly women. In healthy people, more than 50 billion cells die daily as part of a normal biological mechanism: replacing…

Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections

Challenge: Despite the availability of antibiotics, bacterial infections remain a major and growing health threat. Antibiotic resistance is a leading cause of deadly hospital-acquired infections worldwide. In 2017, the World Health Organization published a list of high-level threats bacteria for which new antibiotics are urgently needed. Among them, Staphylococcus aureus (SA) and its persistent forms,…

Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment

Challenge: Respiratory tract infections (RTI) are a leading cause of morbidity, mortality, and hospitalizations globally. Yet, many cases of RTI still go undiagnosed and RTI is often treated empirically because the etiologic agent(s) is unidentified. The current diagnostic approach is complex and often takes days to weeks. It may also fail to detect a broad…

Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets

Challenge: The design of superior biologic therapeutics such as monoclonal antibodies, single-domain antibodies, and engineered proteins requires optimizing their ability to bind to disease targets. Antibodies offer many advantages over small molecules in treating diseases, but the process for generating them is complex, expensive and often requires further steps of affinity maturation to achieve the…